Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma
Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitar ...
TSH-secreting pituitary adenoma
Intervention name : Lanreotide Acetate INN of the intervention : Lanreotide Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : LanreotideAcetate INN of the intervention : Lanreotide Dosage And administration o ...